Pasithea Therapeutics Announces FDA Acceptance of IND
Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3....
Source: globenewswire.com
As 004 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from As 004. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In As 004 Today - Breaking & Trending Today
Pasithea Announces Receipt Of FDA Response Of Pre-IND Meeting For PAS-004 Clinical Development
Biotechnology company Pasithea Therapeutics Corp. (KTTA) announced Wednesday receipt of written responses to questions submitted for a Type 2 pre-Investigational New Drug Application (IND) meeting with the U.
Source: rttnews.com
Pasithea Therapeutics Announces Completion of GMP
-- Represents the final step before submission of Investigational New Drug (IND) application to FDA, expected in the second half of 2023 --...
Source: globenewswire.com